KR20240093915A - 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 - Google Patents

모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 Download PDF

Info

Publication number
KR20240093915A
KR20240093915A KR1020247017366A KR20247017366A KR20240093915A KR 20240093915 A KR20240093915 A KR 20240093915A KR 1020247017366 A KR1020247017366 A KR 1020247017366A KR 20247017366 A KR20247017366 A KR 20247017366A KR 20240093915 A KR20240093915 A KR 20240093915A
Authority
KR
South Korea
Prior art keywords
mosunetuzumab
lenalidomide
dose
subject
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017366A
Other languages
English (en)
Korean (ko)
Inventor
캐서린 그래니어
안드리아 냅
치-정 리
캐롤 엘라인 오'헤어
에크체첵 퍼레브
마이클 씨. 웨이
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 제넨테크, 인크.
Publication of KR20240093915A publication Critical patent/KR20240093915A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247017366A 2021-10-29 2021-10-29 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 Pending KR20240093915A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Publications (1)

Publication Number Publication Date
KR20240093915A true KR20240093915A (ko) 2024-06-24

Family

ID=86158448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017366A Pending KR20240093915A (ko) 2021-10-29 2021-10-29 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법

Country Status (7)

Country Link
JP (2) JP7846761B2 (https=)
KR (1) KR20240093915A (https=)
AU (1) AU2021471006A1 (https=)
CA (1) CA3236111A1 (https=)
MX (1) MX2024005105A (https=)
PE (1) PE20241211A1 (https=)
WO (1) WO2023075798A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009843A (ja) * 2024-06-25 2026-01-21 ジェネンテック， インコーポレイテッド 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法
WO2026050474A1 (en) * 2024-08-28 2026-03-05 Genentech, Inc. Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020275415B2 (en) * 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma

Also Published As

Publication number Publication date
JP2024540044A (ja) 2024-10-31
JP7846761B2 (ja) 2026-04-15
PE20241211A1 (es) 2024-06-06
CA3236111A1 (en) 2023-05-04
WO2023075798A9 (en) 2023-06-29
AU2021471006A1 (en) 2024-05-16
MX2024005105A (es) 2024-05-14
JP2026004356A (ja) 2026-01-14
WO2023075798A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
AU2021374594B2 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CN110636861B (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
TWI888665B (zh) 抗cd20/抗cd3雙特異性抗體之皮下給藥
JP2026004356A (ja) モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法
US20250320298A1 (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20240287182A1 (en) Methods and compositions for treating cancer
US20260055204A1 (en) Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US20220380466A1 (en) Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies
JP2026500084A (ja) 多発性骨髄腫の治療方法および診断方法
US20230190932A1 (en) Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide
US20260078198A1 (en) Methods for treating cancer using subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法
HK40110052A (zh) 用於治疗癌症的方法和组合物
HK40102568A (zh) 用於使用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物的治疗的给药
JP2025517650A (ja) 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240524

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240524

Comment text: Request for Examination of Application

PG1501 Laying open of application